A Phase II, Multi-centre, Open label, Randomised Study to Evaluate the Anti-tumour Activity of Roginolisib (IOA-244) in Patients with Advanced/Metastatic Ocular/Uveal Melanoma

A new tablet called roginolisib is being tested against the standard treatment for patients whose uveal melanoma—a rare eye cancer—has spread to other parts of the body. Uveal melanoma that has metastasised is notoriously difficult to treat, and patients currently have limited options once the cancer spreads. Roginolisib works differently from existing therapies: it blocks a specific type of immune cell (T-reg cells) that normally dampens the body’s own immune response, allowing the immune system to attack the tumour more effectively. Early studies suggest this approach could improve survival where other treatments have failed. If the trial shows that roginolisib extends survival, it would become a new, tablet-based treatment option for a patient group that currently has few. The study also compares two dose levels to find the best balance between effectiveness and side effects, and tracks how the drug interacts with the body and affects patients’ quality of life. Success would not change daily life for most people, but it would directly address a critical gap in cancer care for a specific, underserved patient population.